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ABSTRACT 
We investigated cerebrospinal fluid (CSF) concentrations of the postsynaptic biomarker 
neurogranin at baseline in cognitively healthy controls (HC) compared to individuals with mild 
cognitive impairment (MCI), patients with Alzheimer's disease (AD) dementia, and patients with 
frontotemporal dementia (FTD). CSF neurogranin was quantified using an in-house 
immunoassay in a cross-sectional multicenter study of 108 participants [AD dementia (n = 35), 
FTD (n = 9), MCI (n = 41), cognitively HC (n = 23)]. CSF neurogranin concentrations were 
significantly higher in AD patients compared with both HC subjects and FTD patients, 
suggesting that increased CSF neurogranin concentrations may indicate AD-related 
pathophysiology. CSF neurogranin was independently associated with both total tau and 
hyperphosphorylated tau proteins, whereas a non-significant correlation with the 42-amino acid-
long amyloid-β peptide was evident. CSF neurogranin, however, was not superior to core AD 
biomarkers in differentiating HC from the three diagnostic groups, and it did not improve their 
diagnostic accuracy. We conclude that further classification and longitudinal studies are required 
to shed more light into the potential role of neurogranin as a pathophysiological biomarker of 
neurodegenerative diseases. 
 
 
 
INTRODUCTION  
Synaptic pathology plays a critical role in Alzheimer’s disease (AD)1,2 and correlates with 
cognitive decline.3-6 Because “synapse failure” is increasingly recognized as a hallmark of AD,7 
synaptic markers hold promise for the diagnosis and monitoring of this condition. Neurogranin – 
a postsynaptic protein mainly localized into dendritic spines of neurons within associative 
cortical areas8-10 – is involved in synaptic plasticity.11 Neurogranin expression is significantly 
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lower in the cortex and hippocampus of post-mortem AD brains versus controls.2,12 Compared 
with healthy controls (HCs), CSF neurogranin concentrations are increased in AD13 and mild 
cognitive impairment (MCI) converting into AD (MCI-AD).14-16 Moreover, neurogranin predicts 
MCI to AD dementia progression,14,17,18 and the rate of cognitive decline,14 and correlates 
longitudinally with hippocampal atrophy rates,17,19 as well as with future reduction in cortical 
glucose metabolism assessed by 18F-Fluorodeoxyglucose-PET (18F-FDG-PET).17 
Herein, we investigated the diagnostic accuracy of CSF neurogranin in distinguishing clinical 
AD dementia patients from HCs and frontotemporal dementia (FTD) patients. Furthermore, we 
examined neurogranin diagnostic accuracy across the spectrum of AD pathology using an 
unbiased descriptive categorization system, the “A/T/N” scheme, based on core AD biomarkers 
and independent of cognitive impairment severity.20 It includes three biomarker categories 
reflecting AD pathophysiology, where “A” refers to amyloid-beta (Aβ) pathology, “T” to tau 
pathology, and “N” to neurodegeneration. To this end, we tested whether CSF neurogranin 
distinguished HCs from I) AD pathology patients (presenting decreased CSF concentrations of 
Aβ1-42 peptide and increased amounts of total tau (t-tau) or hyperphosphorylated tau (p-tau) 
protein),21 II) patients showing tau pathology only, and III) patients with Aβ pathology only.  
We also assessed the ability of neurogranin to discriminate AD pathology from FTD. 
 
 
 
MATERIALS AND METHODS  
Standard protocol approvals, registrations, and patient consents  
The study was conducted in accordance with the tenets of the Declaration of Helsinki and was 
approved by the local Ethical Committees at each participant university. All participants or their 
representatives gave written informed consent for the use of their clinical data for research 
purposes. 
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Study participants  
The research was designed as a multicentre cross-sectional study retrospectively conducted in 
a convenience series from three independent European academic AD research centres and 
memory clinics. A total of 108 individuals were included. Specifically, 35 participants were 
recruited from the Institute of Memory and Alzheimer’s Disease (Institut de la Mémoire et de la 
Maladie d’Alzheimer, IM2A) at Pitié-Salpêtrière University Hospital in Paris (France), 57 from 
the German Centre for Neurodegenerative Diseases (DZNE) in Rostock (Germany), and 16 from 
the Institute of Neuroscience and Physiology at Sahlgrenska University Hospital in Mölndal 
(Sweden).  
 
Patient stratification 
Categorization according to the clinical diagnostic approach (“Level I”)  
The clinical diagnosis of AD dementia was performed according to the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) consensus criteria.22 The clinical diagnosis of MCI 
was based on MCI core clinical criteria.23 The diagnosis of the FTD was performed according to 
the consensus on clinical diagnostic criteria of 1998.24 HCs were individuals who I) volunteered 
for a lumbar puncture, II) showed a negative history of neurological or psychiatric diseases, and 
III) had a Mental-State Examination (MMSE) score between 27 and 30.  
Of the 23 cognitively HCs (first group), two individuals from the Gothenburg cohort showed 
CSF t-tau concentrations higher than the established cut-off value. Being asymptomatic-at-risk 
of AD21 or preclinical AD.25 they were excluded from further analyses. The second group 
consisted of 41 clinically defined MCI cases.23 The third and fourth groups included 35 AD 
patients21 and 9 FTD patients, respectively (Figure 1).24  
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Categorization following the A/T/N system (“Level II”) 
AD and MCI patient classification followed the biomarker-based descriptive stratification 
model (“A/T/N” system) recently proposed by Jack and colleagues.20 It contemplates 3 binary 
(positive/negative) categories: “A” referring to an amyloid biomarker (CSF Aβ1-42 or amyloid-
PET), “T” to a tau pathology biomarker (CSF p-tau or tau-PET), and “N” to a quantitative or 
topographic biomarker of neurodegeneration or neuronal injury [CSF t-tau, 18F-FDG-PET, or 
structural MRI]. Because each individual score is displayed with an “A±/T±/N±” arrangement, 
eight different categories are generated.20 Notably, this stratification model is linked to the 
biomarker categorization frameworks – namely the International working group-2 (IWG-2) 
criteria21 and the National Institute on Aging-Alzheimer’s Association (NIA-AA) 
guidelines22,23,25 – and is able to chart both diagnostic classification criteria. Here, we applied a 
simplified version of the original A/T/N model by including only core neurochemical markers 
(CSF Aβ1-42, t-tau, and p-tau). Overall, 5 categories were established as follows: Group 1, 
cognitively HCs (n = 21), a priori defined as [A-/T-/N-], i.e. negative for all the core biological 
markers; Group 2, [A-/T-/N-] (n = 15), including 2 patients diagnosed with AD dementia and 13 
MCI patients negative to both Aβ and tau markers; Group 3, [A-/T±/N+, A-/T+/N±] (n = 15), 
including 6 AD dementia patients and 9 MCI cases all positive to only tau markers; Group 4, 
[A+/T-/N-] (n = 13), including 5 patients clinically diagnosed with AD dementia and comprising 
8 MCI cases displaying positivity to only Aβ; Group 5, [A+/T±/N+, A+/T+/N±] (n = 33), 
including 22 AD dementia patients in line with the IWG-2 criteria21 and the NIA-AA 
guidelines22 comprising 11 prodromal AD26 or MCI due to AD cases,23 all showing positivity to 
both Aβ and tau markers. Finally, the FTD participants (n = 9) (Group 6) included seven patients 
who were both Aβ1-42 and tau-negative, one patient who was Aβ1-42 negative and tau positive, 
and one patient who was Aβ1-42-positive and tau-negative. According to the IWG-2 criteria, the 
latter participant should be defined as a case of FTD and not as a patient with a frontal variant of 
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AD.21 Of note, since the A/T/N system is not directly applicable to FTD, this last group (VI) was 
examined exclusively in terms of clinical diagnosis (Figure 1).  
 
CSF sampling  
A diagnostic lumbar puncture was performed in all participants. All CSF samples included in 
the three study cohorts were collected in polypropylene tubes, centrifuged at 1000 g for 10 min 
at +4°C (samples collected at IM2A in Paris), 1500 g for 10 min at +4°C (samples collected at 
DZNE in Rostock), 1800 g for 10 min at +4°C (samples collected at Mölndal Clinical 
Neurochemistry Laboratory). The collected supernatant was aliquoted and stored at –80°C 
pending biochemical analysis.  
 
Immunoassays for CSF core biomarkers  
For the Paris cohort, CSF analyses of Aβ1-42, t-tau, p-tau were performed at the Laboratory of 
Biochemistry, Unit of Biochemistry of Neurometabolic diseases, Pitié-Salpêtrière University 
Hospital of Paris. For the Rostock cohort, CSF analyses were executed in two different units: the 
Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical Centre, 
after 06/2012, and the Laboratory of Neurochemistry, Department of Neurology, Göttingen 
University Medical Centre, before 06/2012. For the Göteborg cohort, CSF analyses were 
executed at the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital, 
Mölndal. CSF Aβ1-42, t-tau, and tau phosphorylated at threonine 181 (p-tau181) concentrations 
were measured using established sandwich ELISA methods, INNOTEST β-AMYLOID(1-42),27 
INNOTEST hTAU-Ag,28 and INNOTEST Phospho-Tau[181P]29 (Fujirebio Europe NV, Gent, 
Belgium), respectively. All analyses were performed by board-certified laboratory technicians 
blinded to clinical information. CSF biomarkers abnormalities were defined based on reference 
values currently utilized in each memory clinic: at IM2A in Paris, Aβ1-42 <500 pg/mL, t-tau >450 
pg/mL, p-tau181 >60 pg/mL; at DZNE in Rostock, Aβ1-42 <567 pg/mL, t-tau >512 pg/mL, p-
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tau181 >66 pg/mL for the CSF samples measured before 06/2012 and Aβ1-42 <450 pg/mL, t-tau 
>450 pg/mL, p-tau181 >62 pg/mL for the CSF samples measured after 06/2012; at Mölndal 
Clinical Neurochemistry Laboratory, Aβ1-42 <550 pg/mL, t-tau >400 pg/mL, p-tau181 >80 pg/mL.  
 
Immunoassay for CSF neurogranin  
All CSF neurogranin analyses were performed at the Clinical Neurochemistry Laboratory at 
the Sahlgrenska University Hospital, Mölndal, Sweden. We used the same methodology as the 
one employed in a previous study.14 In short, CSF neurogranin was measured using an in-house 
ELISA assay based on the monoclonal antibody Ng7 (epitope including amino acids 52–65 on 
neurogranin) for capture, a polyclonal neurogranin anti-rabbit antibody (ab23570; Upstate 
Biotechnology, Lake Placid, NY, USA) for detection, and full-length neurogranin protein as 
calibrator. All analyses were performed on one occasion with randomized samples using one 
batch of reagents by board-certified laboratory technicians blinded to clinical information to 
avoid bias.  
 
Statistical Analysis  
The associations of diagnostic groups with sex and age were assessed with Fisher's exact tests 
and nonparametric Kruskal-Wallis (KW) tests, respectively. All neurogranin values were 
initially adjusted for age, sex, and site using nonparametric regression. This step allowed age-, 
sex-, and site- independent assessment of the diagnostic potential of neurogranin while foregoing 
assumptions of normality. Whenever the result of the KW test was statistically significant (P < 
0.05), post-hoc groupwise comparisons of neurogranin values were performed with the 
Conover's test for multiple comparisons. Results of post-hoc testing were corrected for multiple 
comparisons using a False Discovery Rate (FDR) procedure (α = 0.05). We then evaluated the 
diagnostic potential of neurogranin using logistic regression within a Leave-One-Out Cross-
Validation (LOO-CV) approach in the following a priori comparisons: AD versus HCs, AD 
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versus FTD, in Level I of categorization; HCs versus [A-/T±/N+, A-/T+/N±], HCs versus 
[A+/T-/N-], HCs versus [A+/T±/N+, A+/T+/N±], and [A+/T±/N+, A+/T+/N±] versus FTD, in 
Level II. In this analysis, age-, sex-, and site-adjusted neurogranin values were entered as 
predictors and the diagnostic group was entered as the dependent variable. After model fitting, 
we calculated the area under the receiver operating characteristic (AUROC) curve by pooling 
predictions computed on the test sets from each train-test split in the LOO-CV procedure. 
Successively we computed its associated confidence intervals using a bootstrap procedure30 
(100000 bootstraps). The discriminatory ability of neurogranin to correctly allocate participants 
to diagnostic groups was classified as follows: excellent (AUROC 0.90-1.00), good (AUROC 
0.80-0.89), fair (AUROC 0.70-0.79), poor (AUROC 0.60-0.69), or fail/no discriminatory 
capacity (AUROC 0.50-0.59).31 All statistical analyses were performed in the R statistical 
environment version 3.2.3 (https://www.R-project.org/) under a Linux environment using the 
nonparametric kernel smoothing methods for mixed data types package (np package),32 partial 
ROC (pROC) package,30 and the pairwise multiple comparison of mean ranks (PMCMR) 
package.33 Two-tailed P values < 0.05 were considered statistically significant. 
 
RESULTS  
CSF neurogranin concentrations (Level I)  
Table 1 summarizes the levels of all analytes, combined with demographic and clinical data 
of the population classified according to Level I. Compared with HCs, CSF neurogranin levels 
were significantly increased in AD patients (P = 0.004). Higher CSF neurogranin levels were 
observed in AD group (P = 0.004) compared with FTD group (Figure 2A).  
CSF neurogranin concentrations (Level II) 
Table 2 summarizes the levels of all analytes, combined with demographic and clinical data 
of the population classified according to Level II. Compared with HCs, CSF neurogranin levels 
were significantly increased in patients who were tau-positive only [A-/T±/N+, A-/T+/N±] (P = 
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0.001) and in those positive to both Aβ and tau markers [A+/T±/N+, A+/T+/N±] (P < 0.001). 
These two groups also presented markedly higher CSF neurogranin concentrations compared 
with cases negative for all the core biomarkers [A-/T-/N-] (P < 0.001 for both groups), those 
who were Aβ-positive only [A+/T-/N-] (P < 0.001 for both groups), and FTD patients (P < 
0.001 for both groups) (Figure 2B).  
 
Diagnostic accuracy of neurogranin (Level I)  
We found that CSF neurogranin was able to differentiate HCs from AD dementia patients 
with an AUROC of 0.72 (95% CI, 0.58-0.86) (Figure 3A). CSF neurogranin was also able to 
discriminate AD from FTD with an AUROC of 0.76 (95% CI, 0.55-0.96) (Figure 3B).  
Diagnostic accuracy of neurogranin (Level II) 
We found that CSF neurogranin was able to differentiate cognitively HCs from Group 3 [A-
/T±/N+, A-/T+/N±] with an AUROC of 0.77 (95% CI, 0.60-0.94) (Figure 3C). CSF neurogranin 
was able to discriminate HCs from Group 4 [A+/T-/N-] with an AUROC of 0.55 (95% CI, 0.34-
0.76) (Figure 3D). CSF neurogranin was able to distinguish HCs from Group 5 [A+/T±/N+, 
A+/T+/N±] with an AUROC of 0.85 (95% CI, 0.74-0.95) (Figure 3E). CSF neurogranin was 
able to discern Group 5 [A+/T±/N+, A+/T+/N±] from FTD with an AUROC of 0.85 (95% CI, 
0.64-1.00) (Figure 3F).  
 
 
DISCUSSION  
Results of Level I (Figure 2A) are consistent with previous reports showing increased CSF 
neurogranin levels in AD dementia patients versus HCs.14-19,34,35. Increased CSF neurogranin 
concentrations in AD dementia are most likely caused by the extracellular release of synaptic 
proteins resulting from synaptic dysfunction and loss. Interestingly, higher CSF neurogranin 
concentrations were found in AD dementia versus FTD, suggesting a potential role for 
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neurogranin in discriminating between the two forms of dementia, in line with a prior study.34 
To corroborate the increase of CSF neurogranin as an AD-specific characteristic,35 future 
analyses are needed across a range of different neurodegenerative diseases.  
In Level II, the significantly elevated CSF neurogranin expression detected in all patient 
categories displaying tau pathology (Figure 2B) confirms the previously observed association 
between neurogranin and markers of neuronal injury.13,14,16-18,35 Increased amounts of CSF t-tau 
and other neuronal proteins in AD reflect extensive cortical neuro-axonal degeneration. Owing 
to the correlation between CSF neurogranin and tau levels, higher neurogranin concentrations 
may serve as a proxy for the cortical synaptic degeneration occurring in AD.2,36  
ROC curves, computed in a LOO-CV setting, were used to examine the accuracy of 
neurogranin as an AD diagnostic marker. In Level I, the performances of CSF neurogranin in 
discriminating clinical AD dementia from HCs and FTD were both fair (AUROC 0.72 and 0.76, 
respectively) (Figures 3A and 3B). In Level II, the performances in distinguishing patients with 
AD pathology (i.e. exhibiting positivity to both Aβ and tau markers) from HCs as well as from 
FTD were good (AUROC 0.85 for both comparisons) (Figures 3E and 3F). Consequently, 
neurogranin delivers a higher diagnostic accuracy when the A/T/N classification system (rather 
than clinical criteria) is used. A fair AUROC (0.77) was found for tau positive patients versus 
HCs (Figure 3C), whereas the ability to discriminate between patients who were Aβ-positive 
only and HCs was unsatisfactory (AUROC 0.55) (Figure 3D). These results suggest that CSF 
neurogranin concentrations may reflect mostly tau pathology rather than Aβ pathology.14,18,35 
Differently from the case of tau markers, the link between CSF Aβ and neurogranin appears 
relatively weak and the association between amyloid plaque load and synaptic depletion appears 
very low if not absent at all.14,18,35 Accordingly, Aβ is involved in the initial steps of AD 
pathophysiology rather than in synaptic loss.37  
Some potential caveats of this study merit comment. Owing to the relatively small sample 
size, it was not possible to divide our patients in all groups established by the original A/T/N 
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system when Level II classification was used.20 Because only core CSF biomarkers (and not 
imaging modalities) were used, MCI with AD dementia patients were grouped together for the 
purpose of analysis (Figure 1). Notably, the clinical distinction between MCI and dementia 
might be problematic and time-dependent; accordingly, the IWG-2 criteria define MCI with AD 
pathology as AD in its prodromal stage.21 Owing to the cross-sectional nature of the study, it was 
not possible to differentiate stable-MCI cases from those converting into dementia. Further 
studies are needed to confirm the potential value of neurogranin in predicting MCI to AD 
conversion.17,18 Extensive psychometric data were not available in our study, preventing the 
study of CSF neurogranin levels in relation to different cognitive dimensions. Moreover, the 
quantification of core AD CSF biomarkers was not performed in a centralized manner, 
potentially being subject to inter- and intra-operator variability. This study is largely exploratory 
as it represents the first attempt of utilizing neurogranin as a CSF biomarker for AD diagnosis in 
a clinical setting by applying an original, unbiased biomarker-based model of stratification20) 
(Figure 1). Notably, the A/T/N dissection system addresses the need for a unifying conceptual 
approach to biomarkers employed in AD research. In fact, given its substantially unbiased 
descriptive nature which eludes disease labels, the A/T/N scheme could potentially be employed 
in any framework of existing and upcoming diagnostic criteria. Moreover, it could be, at some 
point, expanded to integrate key biomarkers of other relevant proteinopathies, genetic or 
epigenetic factors,38 and indicators of other pathologies such as cerebrovascular diseases or 
white matter pathologies which appear to impair cognitive function.39 Finally, the multicenter 
design of the study may introduce variation + a comment on how we dealt with this (if we did; 
please feel free to disregard this comment if it is hard to meet it…).  
In conclusion, our cross-sectional study confirms and expands previous findings on the role 
of CSF neurogranin as a biomarker that consistently distinguishes both AD dementia patients 
from HCs. Because neurogranin helps discriminate AD from FTD, its increased CSF 
concentration seems to be AD-specific. Furthermore, the A/T/N system allows improving 
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neurogranin diagnostic accuracy in distinguishing cognitively impaired patients with AD 
pathology and, to a lesser degree, tau pathology from HCs as well as AD pathology from FTD.  
Future studies are needed to investigate whether CSF neurogranin may predict conversion to 
dementia in subjects at risk of developing AD.  
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